Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

弥漫性大B细胞淋巴瘤 医学 耐火材料(行星科学) 淋巴瘤 护理标准 内科学 数据库 生物 计算机科学 天体生物学
作者
Andrew Ip,Alex Mutebi,Tongsheng Wang,Monika Jun,Anupama Kalsekar,Fernando Rivas Navarro,Anthony Wang,Rajesh Kamalakar,Mariana Sacchi,Brian Elliott
出处
期刊:Blood [American Society of Hematology]
卷期号:140 (Supplement 1): 6693-6694 被引量:1
标识
DOI:10.1182/blood-2022-159569
摘要

Introduction: Despite the rapidly evolving therapeutic landscape for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treatment with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents are common components of R/R DLBCL treatment regimens. This study aimed to characterize clinical outcomes in a real-world cohort of patients with R/R DLBCL treated with the above SOC regimens in the second-line or later setting and to assess the impact of patient demographics and clinical characteristics on clinical outcomes. Methods: This retrospective, observational study used data from the COTA electronic health records database (COTA, New York, NY). The study included adults diagnosed with DLBCL between January 1, 2010, and March 31, 2022, treated with ≥ 1 prior systemic line of therapy (LOT), including ≥ 1 anti-CD20 monoclonal antibody-containing regimen. Patients had an evaluable response assessment for these R/R DLBCL treatment regimens: chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents. Treatment outcomes were evaluated using real-world overall response rate (rwORR), real-world complete response (rwCR) rate, real-world duration of response (rwDOR), real-world duration of complete response (rwDOCR) rate, real-world progression-free survival (rwPFS), and overall survival. Subgroup analyses were conducted for patients with ≥ 2 prior LOTs. Logistic regression and Cox proportional hazards regression analyses evaluated the association between outcomes and patient demographics and clinical characteristics. Results: Overall, 573 patients with R/R DLBCL who had ≥ 1 prior LOT were included in the study; of these, 179 patients (31.2%) had ≥ 2 prior LOTs. Median duration of follow-up was 7.7 months. More than one-half (57.1%) were men; 49.9% were aged > 65 years (aged > 75 years, 20.8%) at diagnosis; 82.0% had an ECOG performance status of 0 to 1; 2.8% had prior exposure to chimeric antigen receptor T-cell (CAR T) therapy; 7.0% had prior autologous stem cell transplant; 62.0% had primary refractory disease; 68.6% were refractory to their last LOT; and 67.7% were refractory to their most recent anti-CD20 therapy. Patients experienced worsening outcomes as they progressed through LOTs. In patients with ≥ 1 prior LOT, rwORR was 52% (95% CI: 48-56), rwCR rate was 23% (95% CI: 19-27), median rwPFS was 3.0 (95% CI: 2.8-3.3) months, and median overall survival (mOS) was 12.9 (95% CI: 10.1-16.9) months. In the subgroup with ≥ 2 prior LOTs, rwORR was 40% (95% CI: 33-48), rwCR rate was 13% (95% CI: 8-19), median rwPFS was 2.4 (95% CI: 2.0-2.7) months, and mOS was 6.2 (95% CI: 5.2-10.9) months. In patients with ≥ 3 prior LOTs, rwORR was 34% (95% CI: 23-45), rwCR rate was 8% (95% CI: 3-16), rwDOR was 2.3 (95% CI: 1.3-3.3) months, rwDOCR was 8.5 (95% CI: 2.1-not estimable) months, median rwPFS was 1.9 (95% CI: 1.5-2.5) months, and mOS was 5.1 (95% CI: 3.2-7.3) months. Factors consistently associated with worse efficacy outcomes were primary refractory disease, refractory to last LOT, and refractory to last anti-CD20 therapy (Table). These characteristics indicated elements of a patient population with difficult-to-treat R/R DLBCL, with a 48%-66% lower likelihood of achieving a rwORR; a 45%-101% higher risk of progression; and a 39%-111% higher risk of mortality than those without these characteristics. Discussion: Patients with R/R DLBCL who received an increasing number of prior LOTs, had primary refractory disease, were refractory to their last LOT, were refractory to their last anti-CD20 therapy, or had prior exposure to CAR T therapy had poor outcomes, with an rwORR (rwCR rate) of 40% (13%) and 34% (8%) in patients with ≥ 2 prior LOTs and ≥ 3 prior LOTs, respectively. This is consistent with prior retrospective analyses of pretreated DLBCL (Crump et al, Blood 2017; Hamadani et al, Clin Lymphoma Myeloma Leuk 2022). Conclusions: Outcomes in patients with R/R DLBCL treated with chemotherapy, single-agent rituximab/obinutuzumab, single-agent lenalidomide, or combinations of these agents remain poor, especially those with difficult-to-treat R/R DLBCL. These findings underscore the high unmet need for new, safe, and effective therapies across this population, including the difficult-to-treat R/R DLBCL subgroups. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
热情诗云完成签到,获得积分10
刚刚
科研小帅完成签到,获得积分10
1秒前
1秒前
1秒前
CodeCraft应助杜彦君采纳,获得10
2秒前
3秒前
无妨完成签到,获得积分10
4秒前
愉快尔烟完成签到,获得积分10
5秒前
梅子发布了新的文献求助10
5秒前
安静碧灵发布了新的文献求助10
6秒前
十九世纪完成签到,获得积分10
7秒前
世界完成签到,获得积分10
7秒前
科研通AI2S应助于夜柳采纳,获得10
8秒前
11秒前
海洋球完成签到,获得积分10
12秒前
13秒前
充电宝应助安静碧灵采纳,获得10
14秒前
热情诗云发布了新的文献求助10
15秒前
lk发布了新的文献求助10
16秒前
Chen完成签到,获得积分10
16秒前
22秒前
24秒前
优秀的语兰完成签到,获得积分10
25秒前
小小猪完成签到,获得积分10
26秒前
28秒前
Hayat发布了新的文献求助10
28秒前
周兰兰发布了新的文献求助10
29秒前
30秒前
安静的明辉完成签到,获得积分10
33秒前
布布爱吃炸鸡完成签到,获得积分10
36秒前
周兰兰完成签到,获得积分10
36秒前
36秒前
37秒前
旧旧完成签到 ,获得积分10
38秒前
老八完成签到,获得积分10
40秒前
落寞蓝天发布了新的文献求助10
43秒前
勤奋的热狗完成签到 ,获得积分10
46秒前
happy完成签到,获得积分10
48秒前
51秒前
宜醉宜游宜睡应助lanbing802采纳,获得10
51秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3161053
求助须知:如何正确求助?哪些是违规求助? 2812453
关于积分的说明 7895410
捐赠科研通 2471252
什么是DOI,文献DOI怎么找? 1315934
科研通“疑难数据库(出版商)”最低求助积分说明 631074
版权声明 602094